Emerging evidence highlights that newer antidiabetic agents, such as SGLT2 inhibitors (SGLT2is), GLP-1 receptor agonists (GLP-1 s), and GIP/GLP-1 receptor agonists, demonstrate significant cardiovascular benefits, including reduced risks of heart failure, atherosclerotic events, and mortality in patients with T2D [38,39]. Here, GLP1R is linked to type 2 diabetes mellitus.